Given the number of new diagnoses, and the numerous breast cancer-related deaths caused by anti-estrogen resistance each year, there is a need to identify molecular vulnerabilities in ERα+ tumors for preventing or overcoming anti-estrogen resistance. Here, ESR1 is linked to breast cancer.